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Does taking probiotics routinely with antibiotics
prevent antibiotic associated diarrhoea?
Christopher C Butler professor of primary care medicine, Donna Duncan senior project manager,
Kerenza Hood professor of statistics
Cardiff University, Cardiff CF14 4XN, UK
This is one of a series of occasional articles that highlight areas of
practice where management lacks convincing supporting evidence. The
series adviser is David Tovey, editor in chief, theCochrane Library. This
paper is based on a research priority identified and commissioned by
the National Institute for Health Research’s Health Technology
Assessment programme on an important clinical uncertainty. To suggest
a topic for this series, please email us at uncertainties@bmj.com
Diarrhoea develops in association with antibiotic treatment in
1% to 44%1 2 of cases, and ranges from mild episodes that
resolve when antibiotics are stopped to serious complications
such as toxic megacolon, bowel perforation, and death. Risk is
increased with extremes of age, co-morbidity, oral broad
spectrum antibiotics (particularly clindamycin, β-lactams, and
third generation cephalosporins), prolonged antibiotic duration,
previous antibiotic associated diarrhoea, and hospitalisation.
Probiotics—live microorganisms that, when administered in
adequate amounts, confer a health benefit on the host—are
present in products available in shops as foodstuffs, and in
formulations used for specific therapeutic purposes. Probiotics
are thought to combat antibiotic associated diarrhoea through
restoring resistance to colonisation by pathogenic bacteria after
the normal colonicmicroflora have been damaged by antibiotics,
by breaking down non-absorbable compounds into absorbable
products, by interfering with pathogenic toxins, and by
enhancing immunity. Effects of probiotics vary by strain owing
to differing resistance to gastric acid and bile, ability to colonise
mucosa, and susceptibility to antibiotics.3
Probiotics carry theoretical risks, including infection beyond
the gut and transfer of antibiotic resistant genes. However, so
far, there have been no reports of bacteraemia or fungaemia
attributable to the probiotics in trials included in published
systematic reviews.4-10
Lactobacillus bacteraemia is rare and has a lowmortality rate.11
Cancer, diabetes, broad spectrum antibiotic therapy, organ
transplantation, and abscess may be risk factors for lactobacillus
bacteraemia. Twelve cases of lactobacillus bacteraemia have
been reported in patients taking a probiotic and 24 cases of
fungaemia associated with the probiotic Saccharomyces
boulardii. However, many lactobacillus strains are human
commensals and a review identified only five well documented
published cases where the consumed probiotic strain was the
same as a clinical isolate.11 Mild to moderate gastrointestinal
side effects and rash are generally no more common than in
patients on placebo probiotic.6
Probiotics may therefore be an attractive option for preventing
antibiotic associated diarrhoea because they are cheap (the cost
of preventing one case in selected hospital patients may be as
low as £50; €60, $79)12 and safe.
What is the evidence of uncertainty?
We conducted a review of meta-analyses, updated with
subsequent randomised controlled trials. We searched PubMed,
EMBASE, the Cochrane Library, and Clinical Evidence in
October 2011 for meta-analyses published in the past five years
in English and trials published after their search dates on
probiotics to prevent antibiotic associated diarrhoea using the
search terms “probiotic” and “antibiotic associated diarrhoea
[or diarrhea]”. We excluded prevention studies, small pilot
studies, studies that were not placebo controlled, studies
published only in abstract form, studies focusing on antibiotic
associated diarrhoea caused by a single organism (such as
Clostridium difficile), and systematic reviews without
meta-analysis.
The commonest outcome measure was diarrhoea, defined as
three loose stools in a 24 hour or 48 hour period.⇓ The type of
probiotic tested, study populations, and effect sizes varied widely
between studies, with both statistically significant2 and
non-significant13 14 findings for the primary outcome and widely
differing rates of antibiotic associated diarrhoea. Many of the
trials identified in the systematic reviews were of poor
quality.6 9 18 Reasons included poor allocation concealment,
inadequate power, possible publication bias, variation in
outcome measures, lack of intention to treat analyses, variation
in follow-up duration, lack of cost-benefit data, variation in
illness severity, and the small proportion of eligible patients
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enrolled. We found no head to head comparisons of probiotic
strains.
Is ongoing research likely to provide
relevant evidence?
We searched the Current Controlled Trials database (www.
controlled-trials.com) for ongoing randomised controlled trials
using the previously described search terms. Six placebo
controlled trials are in progress examining the effect of
probiotics in preventing antibiotic associated diarrhoea in
hospitalised patients. Three (ISRCTN57305201,
ISRCTN10768531, and isrctn19604441) are investigating the
effect of a mixed probiotic, VSL#3, containing eight species of
bacteria licensed for use in irritable bowel syndrome, with one
recruiting exclusively from intensive care units
(ISRCTN10768531). One trial (NCT01087892) is investigating
the effect of Actimel, which contains three species
(Lactobacillus casei DN 114 001, Lactobacillus bulgaricus,
and Streptococcus thermophilus) and one (ISRCTN70017204)
is investigating the effect of a probiotic that contains two strains
of Lactobacillus acidophilus (National Collection of Industrial,
Food and Marine Bacteria (NCIMB) 30157 and 30156),
Bifidobacterium bifidum (NCIMB 30153) and Bifidobacterium
lactis (NCIMB30172). One (ISRCTN86623192) is investigating
the effect of S boulardii. These studies will provide information
on probiotics to prevent antibiotic associated diarrhoea in a
wider range of hospitalised patients and may be large enough
to provide information on which subgroups of patients are at
greatest risk and are most likely to benefit.
No randomised controlled trials have specifically assessed the
use of probiotics with antibiotics in care homes. Robust data
are lacking on levels of antibiotic use and on frequency and
severity of associated diarrhoea this setting. Our Probiotics for
Antibiotic Associated Diarrhoea (PAAD) Study
(ISRCTN79548440) is in an observational phase to determine
whether a trial of probiotics to prevent antibiotic associated
diarrhoea is justified and feasible in care homes.
There is an absence or insufficiency of high quality evidence
to support routine use of probiotics to prevent antibiotic
associated diarrhoea in all people, regardless of age,
comorbidity, and care setting. For example, few trials have been
done in primary care,9 and we found none from intermediate
and social care settings. We found no pragmatic, open
implementation studies.
What should we do in the light of
uncertainty?
Good evidence exists to support using probiotics with S
boulardii and Lactococcus rhamnosus GG (ATCC 53103)5 6 7
to prevent antibiotic associated diarrhoea, with emerging
evidence for certain mixed strains that include L casei or L
acidophilus.10 Probiotics also seem to bemore effective at higher
doses.2 6 8 However, because insufficient evidence exists to
support routinely using probiotics for this purpose, and because
of the low incidence and generally mild severity of antibiotic
associated diarrhoea in otherwise healthy people, we recommend
against routine use of probiotics in all people taking antibiotics
to prevent antibiotic associated diarrhoea. Not all probiotics
evaluated as part of clinical trials are commercially available
in the United Kingdom. Nevertheless, probiotics are cheap and
safe, so routine use with antibiotics is justified in frail patients
in hospital and possibly in children. Those who have previously
had antibiotic associated diarrhoea should be offered probiotics
when they are treated with antibiotics, regardless of setting, but
probiotics should be avoided in people who are seriously
immunocompromised. As probiotics seem more effective at
higher doses,2 6 8 doses of at least 50 billion colony forming
units should be used; probiotics should be taken for the duration
of antibiotic treatment and continued for a week thereafter.
Evidence about the effectiveness of many strains is absent or
insufficient. Head to head studies of probiotic strains are needed,
as well as more studies to identify groups of patients at greatest
risk and most likely to benefit, especially in the community and
in intermediate care.
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Table
Table 1| Systematic reviews of randomised placebo controlled trials (RCTs) and subsequent individual trials of probiotics to prevent
antibiotic associated diarrhoea
Outcome (risk ratio) for antibiotic
associated diarrhoea
Intervention: organism in probiotic and
daily dose (colony forming units)
Number of studies and/or total number
of participants, care setting
Reference
(search date)
Systematic reviews
0.47 (95% CI 0.35 to 0.63)S boulardii, ranging from 4×109 to 2×101010 RCTs, 1858 adults, 4 trials in
hospitalised patients, 1 outpatient, 3 in
patients receiving antibiotic treatment for
H pylori infection
McFarland 20105
(1976-2009)
0.56 (95% CI 0.44 to 0.71)3 trials of S boulardii, 1 of L rhamnosus, 4 of
mixed strains that included L casei, L
acidophilus, L bulgaricus, S thermophilus, B
bifidum, and L rhamnosus, range of doses
8 RCTs, 1220 adults, inpatientsAvadhani 201010
(unclear)
Combined 0.43 (95% CI 0.31 to 0.58);
S boulardii 0.37 (95% CI 0.26 to 0.52);
L rhamnosus 0.31 (95% CI 0.13 to 0.72)
6 trials S boulardii, 6 trials L rhamnosus, 6
other single strains, and 7 mixed strains,
ranging from 1×107 to 1×1011 (mean dose
3×109)
25 RCTs, 2810 children and adults,
inpatients and outpatients including H
pylori treatment
McFarland 20066
(1977-2005)
Combined 0.35 (95% CI 0.19 to 0.67);
adults 0.24 (95% CI 0.08 to 0.75);
children 0.44 (95% CI 0.18 to 1.08)
Single agent lactobacillus, ranging from 2×109
to 4×1010
10 RCTs, 1862 children and adults,
inpatients and outpatients
Kale-Pradham 20107
(inception -May 2008)
0.48 (95% C1 0.35 to 0.65)Single (5 L rhamnosus) and mixed, ranging
from 1×710 to 1×1010
19 RCTs, children and adults, inpatients
and outpatients
Sazawal 20069 (inception
-February 2006)
0.44 (95% CI 0.25 to 0.77)2 RCTs lactobacillus GG, one S boulardii, 3
mixed, dose range unclear
6 RCTs, 766 children, inpatients and
outpatients
Szajewska 20064
(1966-December 2005)
Per-protocol analysis 0.49 (95% CI 0.32 to
0.74); intention to treat analysis 0.90 (95% CI
0.50 to 1.63); 5 studies of higher dose (5 to 40
× 109 day) 0.35 (95% CI 0.25 to 47); 3 studies
of low dose (<5×109 day) 0.89 (95% CI 0.53,
1.48)
6 single, 3 mixed containing (alone or in
combination) Lactobacillus spp,
Bifidobacterium spp, Streptococcus spp, S
boulardii, ranging from 8.25×106 to 4×1010
9 RCTs, 1946 children, inpatients and
outpatients
Johnston 20078
(inception to August
2006)
Randomised controlled trials published after search dates of systematic reviews
High dose 0.34 (95% CI 0.20 to 0.60)
Low dose 0.64 (95% CI 0.42 to 0.97); 15.5%
low dose, 28.2% high dose intervention, and
44.1% placebo treated patients developed
diarrhoea
Combination of L acidophilus and L casei in
low (5× 109) or high (10×109) dose
255 adults, inpatients,
744 of 1120 (66.5%) eligible participants
were not recruited
Gao 20102
1.25 (95% CI 0.40 to 3.92); 7.5% intervention
and 6.0% treated placebo patients developed
diarrhoea
L plantarum, 1×1010239 adults, inpatients and outpatients in a
university hospital infectious diseases clinic
Lonnermark 201013
0.54 (95% CI 0.17 to 1.74); 3.9% intervention
and 7.2% placebo treated patients developed
diarrhoea
L rhamnosus and L acidophilus, 2×109214 adults, inpatients, 10 tertiary hospitals
treated for a range of respiratory tract
infections (mostly pneumonia)
Song 201014
0.74 (95%CI 0.53 to 1.02); 21.8% intervention
and 29.4% placebo treated patients developed
diarrhoea
L acidophilus and L casei, 5×1010437 adults, treated for a minimum of 12
hours in a hospital ward or emergency
room in 8 centres
Psaradellis 201015
0.82 (95%CI, 0.54 to 1.43); 18.0% intervention
and 21.9% placebo treated children developed
diarrhoea
Kefir fermented milk from grains containing
Lactococcus lactis, Lactococcus plantarum,
Lactococcus rhamnosus, Lactococcus casei,
Lactococcus lactis subspecies diacetylactis,
Leuconostoc cremoris,Bifidobacterium longum,
Bifidobacterium breve, Lactobacillus
125 children with upper respiratory tract
infections aged 1-5, in primary care
Merenstein 200916
acidophilus, and Saccharomyces florentinus;
doses of organisms not given
0.50 (95% CI 0.06 to 3.50); 2.5% intervention
and 5.3% placebo treated children developed
diarrhoea
B longum, L rhamnosus, and L plantarum,
twice daily at 108
78 children aged 5months to 16 years with
respiratory tract infections, inpatients and
outpatients
Szymanski 200817
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